Clin Lung Cancer 2017 Mar
Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non-Small-Cell Lung Cancer - Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial.
Related Questions
New comment by Radiation Oncologist at McMaster University School of Medicine ( January 18, 2022)
To respond to the query, yes what is stated above is correct. The dose heterogeneity with 60/15 was purposefully designed to be less than SBRT to comply with differences in te...
I see the LungTECH trial dose constraints, but, they seem really conservative when you have something large and close the PBT resulting in use of 60 G...
New answer by Radiation Oncologist at University of Toronto (December 12, 2018)
A very helpful reference based on UK consensus for normal tissue constraints when considering 3, 5, 8 # SABR
https://www.clinicaloncologyonline.net/article/S0936-6555(17)3043...
New comment by Radiation Oncologist at Mon Health ( October 9, 2020)
Thank you.
What would be you field and margins?
New comment by Radiation Oncologist at Tennessee Oncology ( October 29, 2020)
@Matthew L. Mallory! Has been too long. I hope you are doing well. A thought-provoking question (what if level 5 or 6 only?)... I have to, of course, make several assumpt...